Glomerular filtration rate following pediatric liver transplantation - The SPLIT experience

American Journal of Transplantation

Volumn 10, Issue 12, 2010, Pages 2673-2682

  Campbell, K ^a   Ng, V ^b   Martin, S ^c   Magee, J ^d   Goebel, J ^a   Anand, R ^e   Martz, K ^e   Bucuvalas, J ^e  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

^c UNIVERSITY OF MONTREAL   (Canada)

^d UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^e EMMES CORPORATION   (United States)

Author keywords

glomerular filtration rate; long term outcomes; multicenter studies; pediatric liver transplantation; renal dysfunction

Indexed keywords

CYCLOSPORIN; TACROLIMUS;

AGE; ARTICLE; BILE DUCT ATRESIA; CARDIOVASCULAR DISEASE; CHILD; CHRONIC CHOLESTATIC LIVER DISEASE; CLINICAL TRIAL; COHORT ANALYSIS; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; CRYPTOGENIC CIRRHOSIS; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; FUNCTIONAL ASSESSMENT; GLOMERULUS FILTRATION RATE; HEIGHT; HEPATIC ARTERY THROMBOSIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IMPLANT REGISTRY; KIDNEY DYSFUNCTION; KIDNEY GRAFT REJECTION; KIDNEY MASS; LIVER FAILURE; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; METABOLIC LIVER DISEASE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PEDIATRIC SURGERY; POSTOPERATIVE COMPLICATION; POSTOPERATIVE PERIOD; PRESCHOOL CHILD; PRIORITY JOURNAL; RETRANSPLANTATION; RISK FACTOR;

EID: 78649830375     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2010.03316.x     Document Type: Article

References (51)

1. Fisher NC, Nightingale PG, Gunson BK, Lipkin GW, Neuberger JM,. Chronic renal failure following liver transplantation: A retrospective analysis. Transplantation 1998; 66: 59-66.
2. Tsimaratos M, Viard L, Kreitmann B, et al,. Kidney function in cyclosporine-treated paediatric pulmonary transplant recipients. Transplantation 2000; 69: 2055-2059.
3. Platz KP, Mueller AR, Blumhardt G, et al,. Nephrotoxicity following orthotopic liver transplantation. A comparison between cyclosporine and FK506. Transplantation 1994; 58: 170-178. (Pubitemid 24236210)
4. Gonwa TA, Poplawski SC, Husberg BS, Nery JR, Klintmalm GB,. Cyclosporine nephrotoxicity in orthotopic liver transplantation. Transplant Proc 1988; 20 (3 Suppl 3): 401-404.
5. Wheatley HC, Datzman M, Williams JW, Miles DE, Hatch FE,. Long-term effects of cyclosporine on renal function in liver transplant recipients. Transplantation 1987; 43: 641-647.
6. Devineni R, McKenzie N, Keown P, Kostuk W, Stiller C, Silver M,. Cyclosporine in cardiac transplantation. Can J Surg 1984; 27: 252-254.
7. Myers BD, Ross J, Newton L, Luetscher J, Perlroth M,. Cyclosporine-associated chronic nephropathy. N Engl J Med 1984; 311: 699-705.
8. Gratwohl A, Speck B, Wenk M, et al., Cyclosporine in human bone marrow transplantation. Serum concentration, graft-versus-host disease, and nephrotoxicity. Transplantation 1983; 36: 40-44.
9. Powell-Jackson PR, Young B, Calne RY, Williams R,. Nephrotoxicity of parenterally administered cyclosporine after orthotopic liver transplantation. Transplantation 1983; 36: 505-508.
10. Ojo AO, Held PJ, Port FK, et al,. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003; 349: 931-940.
11. Gonwa TA, Mai ML, Melton LB, et al,. End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: Risk of development and treatment. Transplantation 2001; 72: 1934-1939.
12. Sarwal M, Pascual J,. Immunosuppression minimization in pediatric transplantation. Am J Transplant 2007; 7: 2227-2235.
13. McDiarmid SV,. Renal function in pediatric liver transplant patients. Kidney Int Suppl 1996; 53: S77-S84.
14. Bucuvalas JC, Campbell KM, Cole CR, Guthery SL,. Outcomes after liver transplantation: Keep the end in mind. J Pediatr Gastro enterol Nutr 2006; 43 (Suppl 1): S41-S48.
15. Lane PH,. Puberty and chronic kidney disease. Adv Chronic Kidney Dis 2005; 12: 372-377.
16. Lane PH, Snelling DM, Hollman A, Langer WJ,. Puberty permits increased expression of renal transforming growth factor-beta1 in experimental diabetes. Pediatr Nephrol 2001; 16: 1033-1039.
17. Langer WJ, Devish K, Carmines PK, Lane PH,. Prepubertal onset of diabetes prevents expression of renal cortical connective tissue growth factor. Pediatr Nephrol 2008; 23: 275-283.
18. Lane PH,. Diabetic kidney disease: Impact of puberty. Am J Physiol Renal Physiol 2002; 283: F589-600.
19. McDiarmid SV, Ettenger RB, Fine RN, Busuttil RW, Ament ME,. Serial decrease in glomerular filtration rate in long-term pediatric liver transplantation survivors treated with cyclosporine. Transplantation 1989; 47: 314-318.
20. Arora-Gupta N, Davies P, McKiernan P, Kelly DA,. The effect of long-term calcineurin inhibitor therapy on renal function in children after liver transplantation. Pediatr Transplant 2004; 8: 145-150.
21. Bartosh SM, Alonso EM, Whitington PF,. Renal outcomes in pediatric liver transplantation. Clin Transplant 1997; 11 (5 Pt 1): 354-360.
22. Campbell KM, Yazigi N, Ryckman FC, et al,. High prevalence of renal dysfunction in long-term survivors after pediatric liver transplantation. J Pediatr 2006; 148: 475-480.
23. Avitzur Y, De Luca E, Cantos M, et al,. Health status ten years after pediatric liver transplantation-looking beyond the graft. Transplantation 2004; 78: 566-573.
24. Berg UB, Ericzon BG, Nemeth A,. Renal function before and long after liver transplantation in children. Transplantation 2001; 72: 631-637. (Pubitemid 32802744)
25. Herzog D, Martin S, Turpin S, Alvarez F,. Normal glomerular filtration rate in long-term follow-up of children after orthotopic liver transplantation. Transplantation 2006; 81: 672-677.
26. Mention K, Lahoche-Manucci A, Bonnevalle M, et al,. Renal function outcome in pediatric liver transplant recipients. Pediatr Transplant 2005; 9: 201-207.
27. Andrews WA, Arant BS, Fyock B, Gray S, Schlatter MG, Conlin C,. The effect of cyclosporine A on long-term renal function in pediatric liver transplant recipients. Transplant Proc 1991; 23: 1452-1453.
28. Harambat J, Ranchin B, Dubourg L, et al,. Renal function in pediatric liver transplantation: A long-term follow-up study. Transplantation 2008; 86: 1028-1034.
29. Filler G, Sharma AP,. How to monitor renal function in pediatric solid organ transplant recipients. Pediatr Transplant 2008; 12: 393-401.
30. Levey AS, Coresh J, Balk E, et al,. National Kidney Foundation practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Ann Intern Med 2003; 139: 137-147.
31. Schwartz GJ, Haycock GB, Edelmann CM, Jr,., Spitzer A,. A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics 1976; 58: 259-263.
32. Kuczmarski R, Ogden C, Guo S, et al,. 2000 CDC growth charts for the United States: Methods and development. 2002.
33. Pawarode A, Fine DM, Thuluvath PJ,. Independent risk factors and natural history of renal dysfunction in liver transplant recipients. Liver Transpl 2003; 9: 741-747.
34. Sharma P, Welch K, Eikstadt R, Marrero JA, Fontana RJ, Lok AS,. Renal outcomes after liver transplantation in the model for end-stage liver disease era. Liver Transpl 2009; 15: 1142-1148.
35. Burra P, Senzolo M, Masier A, et al,. Factors influencing renal function after liver transplantation. Results from the MOST, an international observational study. Dig Liver Dis 2009; 41: 350-356.
36. Fernandez M, Medina A, Carbajo E, et al,. Prepubertal rats are more resistant to ischemic renal injury and recover more rapidly than adult rats. Exp Nephrol 2000; 8: 299-303.
37. Shimizu MH, Araujo M, Borges SM, De Tolosa EM, Seguro AC,. Influence of age and vitamin E on post-ischemic acute renal failure. Exp Gerontol 2004; 39: 825-830.
38. Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE,. Developmental pharmacology-drug disposition, action, and therapy in infants and children. N Engl J Med 2003; 349: 1157-1167.
39. Fanta S, Niemi M, Jonsson S, et al,. Pharmacogenetics of cyclosporine in children suggests an age-dependent influence of ABCB1 polymorphisms. Pharmacogenet Genomics 2008; 18: 77-90.
40. Fukudo M, Yano I, Yoshimura A, et al,. Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients. Pharmacogenet Genomics 2008; 18: 413-423.
41. Filler G, De Barros VR, Jagger JE, Christians U,. Cyclosporin twice or three times daily dosing in pediatric transplant patients-it is not the same! Pediatr Transplant 2006; 10: 953-956.
42. Cooney GF, Habucky K, Hoppu K,. Cyclosporin pharmacokinetics in paediatric transplant recipients. Clin Pharmacokinet 1997; 32: 481-495.
43. Alonso EM, Shepherd R, Martz KL, Yin W, Anand R,. Linear growth patterns in prepubertal children following liver transplantation. Am J Transplant 2009; 9: 1389-1397.
44. Emerick KM, Rand EB, Goldmuntz E, Krantz ID, Spinner NB, Piccoli DA,. Features of Alagille syndrome in 92 patients: Frequency and relation to prognosis. Hepatology 1999; 29: 822-829.
45. Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation Annual Report of the U.S. Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients: Transplant Data 1997-2006. Rockville, MD; 2007.
46. Studies of Pediatric Liver Transplantation 2007 Annual Report. Rockville, Maryland: Emmes; 2007.
47. Beckebaum S, Klein CG, Sotiropoulos GC, et al,. Combined mycophenolate mofetil and minimal dose calcineurin inhibitor therapy in liver transplant patients: Clinical results of a prospective randomized study. Transplant Proc 2009; 41: 2567-2569.
48. Dell-Olio D, Kelly DA,. Calcineurin inhibitor minimization in pediatric liver allograft recipients. Pediatr Transplant 2009; 13: 670-681.
49. Evans HM, McKiernan PJ, Kelly DA,. Mycophenolate mofetil for renal dysfunction after pediatric liver transplantation. Transplantation 2005; 79: 1575-1580.
50. Tredger JM, Brown NW, Dhawan A,. Calcineurin inhibitor sparing in paediatric solid organ transplantation: Managing the efficacy/toxicity conundrum. Drugs 2008; 68: 1385-1414.
51. Samyn M, Cheeseman P, Bevis L, et al,. Cystatin C, an easy and reliable marker for assessment of renal dysfunction in children with liver disease and after liver transplantation. Liver Transpl 2005; 11: 344-349.